- Published on
Infectious Disease- Coccidioiddomycosis
COCCIDIOIDDOMYCOSIS
ESSENTIALS DESCRIPTION
The dimorphic fungus Coccidioides immitis is the cause of pulmonary and/or extrapulmonary infections caused by coccidioidomycosis.
The incidence of epidemiology • There are roughly 91 instances of coccidioidomycosis for every 100,000 people in the United States. throughout addition to Mexico and Central and South America, C. immitis is endemic throughout the southwestern United States (primarily California, Arizona, and Texas). More and more cases are being identified outside of the endemic areas (travelers or reactivations). • The number of patients grows sharply on a periodic basis.
RISK ELEMENTS
Due to the possibility of late recrudescence of latent infection, patients with immunosuppressive diseases or treatments, such as AIDS, solid-organ transplantation, or lymphoma, should be mindful of even remote exposure to endemic areas. Patients with AIDS who have CD4 counts below 250 cells/mm3 are at a higher risk of developing coccidioidomycosis. Although the precise amount of steroids that indicates an elevated risk has not been determined, patients undergoing immunosuppressive and glucocorticoid therapy are more susceptible to coccidioidomycosis.
PATHOPHYSIOLOGY
A progressive pneumonia or chronic lung infection may occur if the acute pulmonary infection does not go away
• Antifungal treatment should be administered to patients having a history of coccidioidomycosis at the time of engraftment, regardless of whether they are currently infected, according to experience with organ transplantation. Even asymptomatic seropositive transplant recipients should get antifungal treatment during acute rejection episodes.
ETIOLOGY • C. immitis is a soil-dwelling fungus that thrives at 27°C, while 30°C is the ideal temperature for its growth.
COMMON CONNECTED CIRCUMSTANCES
Usually referred to as "Valley fever," this condition can affect immunocompetent persons and more invasively affect immunocompromised patients. History of Diagnosis • One to three weeks following exposure, symptoms appear. A lower respiratory infection with systemic symptoms like the following is the usual presentation: Sputum production, fever, coughing, chest pain, anorexia, and arthritis Sweating; weakness; the development of erythema nodosum or erythema multiforme. • Asymptomatic residual illness in the lungs, typically nodules or thin-walled cavities, affects approximately 5% of infected individuals. • Approximately one out of every 200 individuals infected with C. immitis develops symptomatic extrapulmonary illness. The skin, soft tissues, bone and joints, and meninges are the typical locations. • If immunity is compromised by medicine or illness, sickness outside the lungs may manifest considerably later than the typical one-year period following the original infection. • Although there are many different types of skin involvement, wart-like nodules are the most prevalent. • More than 90% of individuals with joint involvement have unilateral joint lesions.
MEDICAL EXAMINATION
The skin and nerve system should receive particular attention for any involvement. • Since coccidioidal lesions are frequently focused and generate localized symptoms like discomfort, swelling, or ulceration, a thorough evaluation of symptoms and physical examination are usually sufficient to identify the presence of an extrapulmonary infection.
Diagnostic Examination and Interpretation Laboratory
• When a lung nodule is removed due to probable cancer in endemic locations, a history of C. immitis infection is often identified. • Accurate travel history collection is essential for timely detection of coccidioidal illness in patients who are not in endemic areas. Culture, serologic testing, and a positive coccidioidal skin test are the cornerstones of diagnosis. Experienced labs are the ideal places to do serologic testing. In 75% of patients with initial infections, serum IgM antibodies can be momentarily identified. If the illness goes away, the IgG antibody, which is present later, normally goes away in a few months. Seldom do serologic testing result in false positives. Nearly all patients with primary infections have positive skin-test reactions to coccidioidal antigens shortly after symptoms appear, and cross-reactions with other illnesses are uncommon. Patients with primary infections frequently do not have cultures, despite the fact that they are frequently used to diagnosis coccidioidomycosis in patients with disseminated infections. The basilar meninges are typically affected by meningitis. When the CSF fluid is examined, it reveals mononuclear pleocytosis, low glucose, and high protein levels.
Imagining
Hilar adenopathy, a pleural effusion, and infiltrates are possible radiographic findings of the chest. Diabetes, immunosuppressive illnesses or treatments, and late-stage pregnancy are associated ailments that are especially significant risk factors. Lung cancer and other widespread fungal infections are examples of differential diagnosis. First Line of Treatment Medication • Because controlled comparisons between antifungal and placebo regimens have not been conducted, the role of antifungal medication in individuals with mild or severe early infection symptoms is not well established
• Therapy might speed up the resolution of symptoms. Therefore, doctors should determine if a patient's situation calls for treatment with the available oral antifungal drugs on a case-by-case basis
• If treatment is started, 400 mg/d of fluconazole and 200 mg twice daily of itraconazole are appropriate dosing. Generally speaking, recommended therapy courses last three to six months. • The following are some factors that should be considered in favor of therapy: A negative skin test; conditions indicating a high fungal inoculum; and concurrent noncoccidioidal disease Increased host sensitivity, incapacity to function, elevated antibody titers, and infiltrations involving more than half of a lung - Severe night sweats that last more than three weeks - Weight loss of more than 10% Silar adenopathy that is noticeable or chronic; symptoms that last longer than two months
• Prolonged chemotherapy is always recommended for individuals with disseminated illness. • During chemotherapy, pulmonary resection can be used to treat severe hemoptysis or cavities that burst or expand. In order to empty empyemas, seal persistent bronchopleural fistulas, or enlarge lungs that are constrained by lingering illness, surgery may also be necessary. • The preferred medications for treating meningeal illness are fluconazole and itraconazole. • The fact that azole therapy is well tolerated, does not have the toxic effects of amphotericin B, and does not require administration into the cerebrospinal fluid may represent significant advantages in patients with an otherwise fatal illness, even if C. immitis infection cannot be cured and lifelong suppression is necessary. Line Two Chemotherapy is nearly usually recommended once the illness has progressed outside of the lungs. Patients who do not respond to azole treatment are treated with amphotericin B.
PERMANENT CARE FOLLOW-UP ADVICE
• Residual sequelae, many of which have minimal long-term effects, are caused by 5–10% of infections. • The serologic response to C. immitis is typically at least qualitatively intact in those who are more susceptible to infection. The doctor should be aware of the probability of this diagnosis if the patient has a history of travel or residency in endemic areas. A postponed diagnosis can be avoided with routine serologic testing. • Ninety percent of meningitis patients die within a year if treatment is not received, thus early detection is crucial. • Some individuals develop chronic lung disease as a result of their acute pneumonia, which never goes away. This group is disproportionately overrepresented among individuals with diabetes and those with weakened immune systems.
COMPLICATIONS
• Immunocompromised people are more susceptible to the disease, especially if they have extrapulmonary coccidioidal disease. The first year following an organ transplant is the time when patients are most vulnerable to infection. • Meningitis may manifest clinically practically simultaneously with the initial infection and typically develops 6 months after it. Typically, there are no symptoms of meningeal irritation that are typical with bacterial meningitis. The headache is the most typical symptom. There may be focal neurologic problems, fever, weakness, disorientation, sluggishness, seizures, aberrant behavior, stiff neck, diplopia, ataxia, and vomiting.
COCCIDIOIDDOMYCOSIS
ESSENTIALS DESCRIPTION
The dimorphic fungus Coccidioides immitis is the cause of pulmonary and/or extrapulmonary infections caused by coccidioidomycosis.
The incidence of epidemiology • There are roughly 91 instances of coccidioidomycosis for every 100,000 people in the United States. throughout addition to Mexico and Central and South America, C. immitis is endemic throughout the southwestern United States (primarily California, Arizona, and Texas). More and more cases are being identified outside of the endemic areas (travelers or reactivations). • The number of patients grows sharply on a periodic basis.
RISK ELEMENTS
Due to the possibility of late recrudescence of latent infection, patients with immunosuppressive diseases or treatments, such as AIDS, solid-organ transplantation, or lymphoma, should be mindful of even remote exposure to endemic areas. Patients with AIDS who have CD4 counts below 250 cells/mm3 are at a higher risk of developing coccidioidomycosis. Although the precise amount of steroids that indicates an elevated risk has not been determined, patients undergoing immunosuppressive and glucocorticoid therapy are more susceptible to coccidioidomycosis.
PATHOPHYSIOLOGY
A progressive pneumonia or chronic lung infection may occur if the acute pulmonary infection does not go away
• Antifungal treatment should be administered to patients having a history of coccidioidomycosis at the time of engraftment, regardless of whether they are currently infected, according to experience with organ transplantation. Even asymptomatic seropositive transplant recipients should get antifungal treatment during acute rejection episodes.
ETIOLOGY • C. immitis is a soil-dwelling fungus that thrives at 27°C, while 30°C is the ideal temperature for its growth.
COMMON CONNECTED CIRCUMSTANCES
Usually referred to as "Valley fever," this condition can affect immunocompetent persons and more invasively affect immunocompromised patients. History of Diagnosis • One to three weeks following exposure, symptoms appear. A lower respiratory infection with systemic symptoms like the following is the usual presentation: Sputum production, fever, coughing, chest pain, anorexia, and arthritis Sweating; weakness; the development of erythema nodosum or erythema multiforme. • Asymptomatic residual illness in the lungs, typically nodules or thin-walled cavities, affects approximately 5% of infected individuals. • Approximately one out of every 200 individuals infected with C. immitis develops symptomatic extrapulmonary illness. The skin, soft tissues, bone and joints, and meninges are the typical locations. • If immunity is compromised by medicine or illness, sickness outside the lungs may manifest considerably later than the typical one-year period following the original infection. • Although there are many different types of skin involvement, wart-like nodules are the most prevalent. • More than 90% of individuals with joint involvement have unilateral joint lesions.
MEDICAL EXAMINATION
The skin and nerve system should receive particular attention for any involvement. • Since coccidioidal lesions are frequently focused and generate localized symptoms like discomfort, swelling, or ulceration, a thorough evaluation of symptoms and physical examination are usually sufficient to identify the presence of an extrapulmonary infection.
Diagnostic Examination and Interpretation Laboratory
• When a lung nodule is removed due to probable cancer in endemic locations, a history of C. immitis infection is often identified. • Accurate travel history collection is essential for timely detection of coccidioidal illness in patients who are not in endemic areas. Culture, serologic testing, and a positive coccidioidal skin test are the cornerstones of diagnosis. Experienced labs are the ideal places to do serologic testing. In 75% of patients with initial infections, serum IgM antibodies can be momentarily identified. If the illness goes away, the IgG antibody, which is present later, normally goes away in a few months. Seldom do serologic testing result in false positives. Nearly all patients with primary infections have positive skin-test reactions to coccidioidal antigens shortly after symptoms appear, and cross-reactions with other illnesses are uncommon. Patients with primary infections frequently do not have cultures, despite the fact that they are frequently used to diagnosis coccidioidomycosis in patients with disseminated infections. The basilar meninges are typically affected by meningitis. When the CSF fluid is examined, it reveals mononuclear pleocytosis, low glucose, and high protein levels.
Imagining
Hilar adenopathy, a pleural effusion, and infiltrates are possible radiographic findings of the chest. Diabetes, immunosuppressive illnesses or treatments, and late-stage pregnancy are associated ailments that are especially significant risk factors. Lung cancer and other widespread fungal infections are examples of differential diagnosis. First Line of Treatment Medication • Because controlled comparisons between antifungal and placebo regimens have not been conducted, the role of antifungal medication in individuals with mild or severe early infection symptoms is not well established
• Therapy might speed up the resolution of symptoms. Therefore, doctors should determine if a patient's situation calls for treatment with the available oral antifungal drugs on a case-by-case basis
• If treatment is started, 400 mg/d of fluconazole and 200 mg twice daily of itraconazole are appropriate dosing. Generally speaking, recommended therapy courses last three to six months. • The following are some factors that should be considered in favor of therapy: A negative skin test; conditions indicating a high fungal inoculum; and concurrent noncoccidioidal disease Increased host sensitivity, incapacity to function, elevated antibody titers, and infiltrations involving more than half of a lung - Severe night sweats that last more than three weeks - Weight loss of more than 10% Silar adenopathy that is noticeable or chronic; symptoms that last longer than two months
• Prolonged chemotherapy is always recommended for individuals with disseminated illness. • During chemotherapy, pulmonary resection can be used to treat severe hemoptysis or cavities that burst or expand. In order to empty empyemas, seal persistent bronchopleural fistulas, or enlarge lungs that are constrained by lingering illness, surgery may also be necessary. • The preferred medications for treating meningeal illness are fluconazole and itraconazole. • The fact that azole therapy is well tolerated, does not have the toxic effects of amphotericin B, and does not require administration into the cerebrospinal fluid may represent significant advantages in patients with an otherwise fatal illness, even if C. immitis infection cannot be cured and lifelong suppression is necessary. Line Two Chemotherapy is nearly usually recommended once the illness has progressed outside of the lungs. Patients who do not respond to azole treatment are treated with amphotericin B.
PERMANENT CARE FOLLOW-UP ADVICE
• Residual sequelae, many of which have minimal long-term effects, are caused by 5–10% of infections. • The serologic response to C. immitis is typically at least qualitatively intact in those who are more susceptible to infection. The doctor should be aware of the probability of this diagnosis if the patient has a history of travel or residency in endemic areas. A postponed diagnosis can be avoided with routine serologic testing. • Ninety percent of meningitis patients die within a year if treatment is not received, thus early detection is crucial. • Some individuals develop chronic lung disease as a result of their acute pneumonia, which never goes away. This group is disproportionately overrepresented among individuals with diabetes and those with weakened immune systems.
COMPLICATIONS
• Immunocompromised people are more susceptible to the disease, especially if they have extrapulmonary coccidioidal disease. The first year following an organ transplant is the time when patients are most vulnerable to infection. • Meningitis may manifest clinically practically simultaneously with the initial infection and typically develops 6 months after it. Typically, there are no symptoms of meningeal irritation that are typical with bacterial meningitis. The headache is the most typical symptom. There may be focal neurologic problems, fever, weakness, disorientation, sluggishness, seizures, aberrant behavior, stiff neck, diplopia, ataxia, and vomiting.
0 Comments
